No-charge genetic testing for primary hyperoxaluria type 1

Alnylam has partnered with Invitae to offer genetic testing at no charge for individuals who may carry gene mutations known to be associated with primary hyperoxaluria type 1 (PH1).

The Alnylam Act® program was developed to reduce barriers to genetic testing and counseling in order to help people make more informed decisions about their health.

While Alnylam provides financial support for this program, tests and services are performed by independent third parties. Healthcare professionals must confirm that patients meet certain criteria to use the program. Alnylam receives de-identified patient data from this program, but at no time does Alnylam receive patient identifiable information. Alnylam receives contact information for health care providers who use this program. Genetic testing is available in the US and Canada. Genetic counseling is only available in the US. Healthcare professionals who use this program have no obligation to recommend, purchase, order, prescribe, promote, administer, use or support any Alnylam product.

What is primary hyperoxaluria type 1?

The primary hyperoxalurias are inherited disorders of glyoxylate metabolism in which hepatic enzyme deficiencies result in excessive endogenous production of oxalate.  The excess oxalate cannot be degraded and is excreted in large amounts by the kidneys, resulting in accumulation of oxalate and progressive kidney disease.1

Most patients with primary hyperoxaluria type 1 present with signs or symptoms related to kidney stones, which are observed in 65% of patients before 10 years of age1 and in up to 80% before 20 years of age.2

  1. Edvardsson VO, Gldfarb DS, Lieske JC et al. Hereditary causes of kidney stones and chronic kidney disease. Pediatr Nephrol. 2013,28:1923-42.
  2. Hoppe B, Beck BB, Milliner DSD.  The primary hyperoxalurias. Kidney Int. 2009;75:1264-71.

Eligibility

Learn more

Ordering instructions

Learn more

Program eligibility

To be eligible for the Alnylam Act PH1 program, patients must have a family history or suspected diagnosis of primary hyperoxaluria with one or more of the following symptoms:

  • Family history of primary hyperoxaluria
  • Pediatric kidney stone(s)
  • Pediatric renal dysfunction or failure
  • Recurrent nephrolithiasis or urolithiasis
  • Nephrocalcinosis
  • Oxalate crystals identified in any biologic fluid or tissue

Benefits of testing

The benefits of genetic testing include the ability to:

  • Identify risk of disease for patients and their family members
  • Shorten the time to diagnosis and help prevent misdiagnosis
  • Help patients consider clinical trials
  • Provide information about support services such as patient advocacy organizations

Genetic testing with Invitae

The Alnylam Act® program offers testing with either one of the following two panels:

Invitae Primary Hyperoxaluria Panel

The Invitae Primary Hyperoxaluria Panel tests three genes associated with primary hyperoxaluria: AGXT, GRHPR, and HOGA1.

View panel

Invitae Nephrolithiasis Panel

The Invitae Nephrolithiasis Panel tests 35 genes associated with nephrolithiasis, including AGXT, GRHPR, and HOGA1.

View panel

Please note: this program does not offer the ability to re-requisition to another panel. Please be sure to select the panel that is most appropriate for your patient.

Ordering made easy

Place your order Collect a sample Results

To place a paper-based order, download the paper order form.

To place an order online:

  1. Sign up for an account and start a new order
  2. Under Test Selection, select the Partnership Programs tab and enter PH1 in the Invitae Partner Code field
  3. Use the search bar to select either the Primary Hyperoxaluria Panel or the Nephrolithiasis Panel
  4. Fill in the required patient information
  5. Under Billing Information, select Institutional Billing and leave all fields blank
  6. Complete the Order Authorization section and submit the order
  7. Fill out, print and sign the eligibility criteria form, which includes a required physician consent, and include it with the specimen
To collect a specimen:
  1. Order a specimen collection kit (blood or saliva)*

  2. Collect the specimen and ship it back to Invitae

  3. Include the signed eligibility criteria form with the specimen

  4. For additional information, see specimen and shipping requirements
To receive results:
  1. Once Invitae receives the sample, you will receive the results in 10–21 calendar days, on average

  2. If you created an online account, you can view the status of your order by logging into your account

  3. You will receive a notification email once the test results are ready

*Blood, saliva, and assisted saliva samples are accepted; DNA samples are not accepted for this program.

Support every step of the way

Client services

Available to answer your questions or help you through the testing process.

CONTACT

Sponsored genetic counseling

Alnylam is sponsoring no-charge, telephone-based genetic counseling for patients in the US. For assistance with genetic counseling or to schedule an appointment, please call InformedDNA, the third-party genetic counseling service, at 888-475-3128.

Learn more

Resource for your patients

Confidence begins with quality

  • Commitment to quality: Invitae’s >1000 patient peer-reviewed study, published in the Journal Molecular Diagnostics, the official journal of the Association for Molecular Pathology, shows equivalence to established standards.
  • Sample options: blood and saliva kits provided free of charge.
  • Strong team: Invitae has more than 300 experts in genetics, bioinformatics, engineering, technology, and commercial development.

About Invitae

Invitae is a genetic information company whose mission is to bring genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Specializing in genetic diagnostics for hereditary disorders, Invitae is aggregating the world’s genetic tests into a single service with better quality, faster turnaround time, and a lower price than most single-gene tests today.


About Alnylam

Alnylam is leading the translation of RNAi as a new class of innovative medicines, with a core focus on RNAi therapeutics toward genetically defined targets for the treatment of serious, life-threatening diseases. RNAi therapeutics offer a modular and reproducible approach for development and commercialization of innovative medicines. Alnylam is sponsoring no-charge, third-party genetic testing and counseling for individuals who may carry gene mutations known to be associated with primary hyperoxaluria type 1. For more information, visit www.AlnylamAct.com.